Reinhard von Roemeling
Director Técnico/Científico/I+D en CURIS, INC. .
Cargos activos de Reinhard von Roemeling
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| CURIS, INC. | Director Técnico/Científico/I+D | 13/08/2019 | - |
Historial de carrera de Reinhard von Roemeling
Antiguos cargos conocidos de Reinhard von Roemeling.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
HUYA Bioscience International LLC
 HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Director Técnico/Científico/I+D | - | - |
Formación de Reinhard von Roemeling.
| Johann Wolfgang Goethe-Universität Frankfurt am Main | Doctorate Degree |
Estadísticas
Internacional
| Estados Unidos | 3 |
| Alemania | 2 |
Operativa
| Chief Tech/Sci/R&D Officer | 2 |
| Doctorate Degree | 1 |
Sectorial
| Health Technology | 3 |
| Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| CURIS, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
HUYA Bioscience International LLC
HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Health Technology |
